Gastroenterology

Back to articles

Proton pump inhibitor use not associated with increased risk of stroke

February 20, 2018
  • Advising on this article:
  • C. Wayne Weart

KEY POINT

Routine use of proton pump inhibitors (PPIs) was not associated with a significant increase in the risk of ischemic stroke after adjustment for multiple risk stroke factors and PPI indications, according to results of a prospective, observational analysis published in Gastroenterology.

SOURCES

Nguyen LH, et al. No significant association between proton pump inhibitor use and risk of stroke after adjustment for lifestyle factors and indication. Gastroenterology. 2017;[Epub ahead of print].

Wang YF, et al. Proton-pump inhibitor use and the risk of first-time ischemic stroke in the general population: A nationwide population-based study. Am J Gastroenterol. 2017;112(7):1084–93.

Sehested TSG, et al. Long-term use of proton pump inhibitors, dose–response relationship, and associated risk of ischemic stroke and myocardial infarction. J Intern Med. 2017;[Epub ahead of print]. 

Recent Articles

2215 Constitution Avenue NW, Washington, DC 20037 Telephone 202-628-4410 Fax 202-783-2351

© 2013 American Pharmacists Association All Rights Reserved.

About the American
Pharmacists Association

The American Pharmacists Association (APhA) is the organization whose members are recognized in society as essential in all patient care settings for optimal medication use that improves health, wellness and quality of life. Through information, education and advocacy, APhA empowers its members to improve medication use and advance patient care.

More info

About APhA DrugInfoLine

APhA DrugInfoLine (ISSN 2162-3015) is a weekly publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not neccessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that the information contained in APhA DrugInfoLine is accurate and current; however, they shall have no ability to any person or entity with regard to claims, losses, or damage caused or alleged to be caused, directly or indirectly by use of any information contained in the publication. All decisions about drug therapy must be based on independent judgement of the clinician.